Palvella Therapeutics, Inc. Common Stock (PVLA)

• Market cap: $156M
• 1 day: 7.09%
• 5 days: 10.50%
• 1 month: -5.89%
• 3 months: 8.26%
• 6 months: 8.26%
• Year to date: 15.75%
• 1 year: 8.26%
• 5 years: 8.26%
• 10 years: 8.26%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $38 174% upside
• Avg. target: $38 174% upside
• High target: $38 174% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 37% 1-year accuracy 127 / 343 met price target

174% upside $38

Buy Reiterated

10 Jan 2025